Multiple Sclerosis
📧 Sign up to get email alerts when something new happens for Multiple Sclerosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-10-28Clinical Trial Update: OER Glibenclamide for Neuropathic Pain in Multiple Sclerosis [Phase 1]
A Phase 1 clinical trial to evaluate glibenclamide for neuropathic pain in multiple sclerosis is listed as not yet recruiting.
-
EMA approval · 2025-10-27EMA Authorised: Lemtrada (alemtuzumab) — Sanofi Belgium
The EMA has authorised Lemtrada (alemtuzumab) for the treatment of multiple sclerosis, with a decision date of 27 October 2025.
-
CLINICAL_TRIALS research · 2025-10-27Clinical Trial Update: Effects of Antiviral Therapies on Epstein-Barr Virus Replication [Phase 2]
Phase 2 clinical trial from Massachusetts General Hospital evaluating antiviral therapies to suppress Epstein-Barr virus replication in peop…
-
CLINICAL_TRIALS trial_result · 2025-10-20Clinical Trial Update: A Pilot Randomized Controlled Trial: CoINTEGRATE [NA]
This entry notes the completion of the CoINTEGRATE pilot randomized controlled trial conducted by the University of Michigan; no specific re…
-
CLINICAL_TRIALS research · 2025-10-20Clinical Trial Update: A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies
This study reviews the safety of diroximel fumarate (VUMERITY) in participants who took the drug during pregnancy and assesses health outcom…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2025-10-20Clinical Trial Update: Effect of Alemtuzumab on Microglial Activation Positron Emission Tomography (PET) in Multiple Sclerosis [Phase 1, Phase 2]
Clinical trial update indicates the Phase 1/Phase 2 study of alemtuzumab for multiple sclerosis has been withdrawn.
-
EMA approval · 2025-10-16EMA Authorised: Avonex (interferon beta-1a) — Biogen Netherlands B.V.
EMA authorised Avonex (interferon beta-1a) for multiple sclerosis. The marketing authorisation holder is Biogen Netherlands B.V., with a dec…
-
CLINICAL_TRIALS research · 2025-10-16Clinical Trial Update: A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS)
This study aims to evaluate the long-term safety of Biogen's multiple sclerosis therapies Vumerity and Tecfidera in people with multiple scl…
-
CLINICAL_TRIALS trial_result · 2025-10-15Clinical Trial Update: A Study to Evaluate the Effect of SAR443820 on Serum Neurofilament Levels in Male and Female Adult Participants With Multiple Sclerosis [Phase 2]
A Phase 2 clinical trial evaluating SAR443820 for reducing serum neurofilament levels in adults with multiple sclerosis has been terminated,…
-
CLINICAL_TRIALS research · 2025-10-15Clinical Trial Update: A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients [Phase 2]
A Phase 2 trial evaluating nasal administration of foralumab in patients with non-active secondary progressive multiple sclerosis is current…
-
CLINICAL_TRIALS trial_result · 2025-10-15Clinical Trial Update: A Closed Loop, Doctor to Patient, Mobile Application for Depression in People With Multiple Sclerosis [NA]
A clinical trial update for a closed-loop mobile application designed to manage depression in people with multiple sclerosis; the study is a…
-
CLINICAL_TRIALS research · 2025-10-14Clinical Trial Update: A Study of the MIND Diet for Persons With Multiple Sclerosis [NA]
A clinical trial update noting a study of the MIND Diet for persons with Multiple Sclerosis, currently recruiting.
-
CLINICAL_TRIALS research · 2025-10-09Clinical Trial Update: Comparing Telehealth-Delivered CBT-I to Web-Based CBT-I to Enhance Sleep, Reduce Fatigue, and Promote Neuroprotection [Phase 2]
A Phase 2 clinical trial at University of Kansas Medical Center comparing telehealth-delivered cognitive behavioral therapy for insomnia (CB…
-
EMA approval · 2025-10-08EMA Authorised: Briumvi (ublituximab) — Neuraxpharm Pharmaceuticals S.L.
The European Medicines Agency authorised Briumvi (ublituximab) for multiple sclerosis, including relapsing-remitting disease, with Neuraxpha…
-
CLINICAL_TRIALS research · 2025-10-08Clinical Trial Update: Relationship Between Cognition, Workforce Participation and Well-Being in Individuals With Multiple Sclerosis
This clinical trial investigates the relationship between cognition, workforce participation, and well-being in individuals with multiple sc…
-
CLINICAL_TRIALS research · 2025-10-06Clinical Trial Update: Prognostic Value of Cerebrospinal Fluid Immunoglobulin Free Light Chains in Patients With Multiple Sclerosis
This study evaluates the prognostic value of cerebrospinal fluid immunoglobulin free light chains in patients with multiple sclerosis and is…
-
CLINICAL_TRIALS research · 2025-10-03Clinical Trial Update: Movement-2-Music: Lakeshore Examination of Activity, Disability, and Exercise Response Study [NA]
Completed clinical trial update for the Movement-2-Music study at the University of Alabama at Birmingham, assessing activity, disability, a…
-
CLINICAL_TRIALS research · 2025-10-03Clinical Trial Update: Chronic Fatigue in Multiple Sclerosis: MS Copilot Boost Solution Compared to Standard Care [NA]
A clinical trial evaluating the MS Copilot Boost Solution versus standard care for chronic fatigue in people with multiple sclerosis; the st…
-
CLINICAL_TRIALS research · 2025-10-02Clinical Trial Update: Central Vein Sign: a Diagnostic Biomarker in Multiple Sclerosis
Update on a clinical trial evaluating the central vein sign as a diagnostic biomarker for multiple sclerosis; the study is active but not re…
-
CLINICAL_TRIALS trial_result · 2025-10-02Clinical Trial Update: MSCopilot Users' Feedback in Real Life - Outcomes Regarding Integration in Patients' pathWay and Users' ExpeRience [NA]
This trial update reports real-world feedback on MSCopilot regarding its integration into patient pathways and user experience for individua…
-
CLINICAL_TRIALS research · 2025-10-02Clinical Trial Update: The Relationship Between Mechanical Properties of Respiratory and Lower Extremity Muscles and Other Parameters in Multiple Sclerosis
This clinical trial update describes a study examining the relationship between the mechanical properties of respiratory and leg muscles and…
-
CLINICAL_TRIALS research · 2025-10-02Clinical Trial Update: Biobank For MS And Other Demyelinating Diseases
Sponsor Accelerated Cure Project for Multiple Sclerosis reports an active biobank study for multiple sclerosis and related demyelinating dis…
-
CLINICAL_TRIALS research · 2025-10-01Clinical Trial Update: Integrating Metabolism, Connectivity, and Mesoscale Imaging at Ultra-high Field to Decipher Mechanisms of Resilience and Neurodegeneration in Neurological Diseases and Healthy Aging
An ongoing sponsor-initiated study is evaluating metabolism, connectivity, and ultra-high-field mesoscopic imaging to uncover mechanisms of …
-
CLINICAL_TRIALS research · 2025-09-30Clinical Trial Update: Serum Neurofilaments and GFAP in Atypical Multiple Sclerosis [NA]
This clinical trial update reports measurements of serum neurofilaments and GFAP in patients with relapsing-remitting and progressive multip…
-
CLINICAL_TRIALS research · 2025-09-29Clinical Trial Update: Hybrid Rehabilitation Approach Through Group Exercise and Telerehabilitation in Patients With Multiple Sclerosis [NA]
Clinical trial update describing a hybrid rehabilitation approach that combines group exercise with telerehabilitation for patients with Mul…